Pandite Arundathy N.
Chief Medical Officer
- Shares
- 30,000
- Price
- $7.01
- Value
- $210,300
STTK
No net buyers or sellers account for the net balance. There is no cluster of three distinct buyers within 30 days. We found no CEO/CFO purchases over 12 months.
Only open-market P purchases and S sales count toward the signal. Vesting, options, taxes and gifts remain in the source data but do not trigger alerts. Rule 10b5-1 trades are shown as informational.
3-month balance
$0.00
0 buyers · 0 sellers
12-month purchases
$250,000
5 distinct insiders
12-month sales
$408,600
1 distinct insiders
Highlighted alerts
17
2 Rule 10b5-1 trades treated as informational
Buying cluster · 30 days
Fewer than three distinct buyers
CEO/CFO purchases · 12 months
No executive purchases found
The same filtered trades as JSON for your scripts, alerts or AI agent, for 5,500+ US companies — plus sentiment, news, financials and breakout setups. Free · every API · 1,000 requests a month · no card required.
STTK overview: breakout setup, X sentiment and insiders in one page →
The SEC XML stores every transaction. Raspberry keeps that evidence, reads the footnotes and separates voluntary open-market activity from vesting, option exercises, gifts, tax withholding, stock purchase and dividend reinvestment plans and pre-programmed 10b5-1 trades.
Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 2, 2026. The plan is intended to execute sales of shares received upon option exercise only as needed to fund the exercise price and estimated tax withholding associated with option exercises under the plan. Under the procedures of the administering broker, acquired shares are first sold to fund the aggregate exercise price and estimated tax withholding with respect to all possible option exercises in a particular order under the plan and only once fully funded will acquired shares be held by the Reporting Person. This transaction represents the final sale of shares needed to fully fund the exercise price and estimated tax withholding for the option exercises under this order of the plan and the remaining shares acquired upon exercise under this order will be held by the Reporting Person. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.000 to $7.030, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This option represents a right to purchase a total of 52,200 shares of the Issuer's common stock, one quarter of which will vest on January 25, 2024, with the remaining three quarters vesting in equal monthly installments through January 25, 2027, subject to the Reporting Person's continued service to the Issuer.
Reason: tax_withholding. The filing footnotes identify tax withholding. The trade is reported under a Rule 10b5-1 plan.
Voluntary purchases and sales; administrative noise stays hidden.
Pandite Arundathy N.
Chief Medical Officer
Ashiya Mona
Director
Ashiya Mona
Director
ORBIMED ADVISORS LLC
Director
ORBIMED ADVISORS LLC
Director
SIEGALL CLAY B
Director
Pandite Arundathy N.
Chief Medical Officer
ORBIMED ADVISORS LLC
Director
ORBIMED ADVISORS LLC
Director
ORBIMED ADVISORS LLC
Director
ORBIMED ADVISORS LLC
Director
ORBIMED ADVISORS LLC
Director
ORBIMED ADVISORS LLC
Director
Ashiya Mona
Director
Ashiya Mona
Director
Ashiya Mona
Director
Ashiya Mona
Director
Ashiya Mona
Director
Ashiya Mona
Director
| Date | Insider | Transaction | Shares | Price | Value | Reading |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | Pandite Arundathy N. Chief Medical Officer | Sale | 30,000 | $7.01 | $210,300 | |
| Jun 11, 2026 | Ashiya Mona Director | Purchase | 208,333 | — | — | |
| Jun 11, 2026 | Ashiya Mona Director | Purchase | 1,041,667 | — | — | |
| Jun 11, 2026 | ORBIMED ADVISORS LLC Director | Purchase | 208,333 | — | — | |
| Jun 11, 2026 | ORBIMED ADVISORS LLC Director | Purchase | 1,041,667 | — | — | |
| Jun 09, 2026 | SIEGALL CLAY B Director | Purchase | 62,500 | $4.00 | $250,000 | |
| May 12, 2026 | Pandite Arundathy N. Chief Medical Officer | Sale | 30,000 | $6.61 | $198,300 | |
| Aug 25, 2025 | ORBIMED ADVISORS LLC Director | Purchase | 1,051,021 | $0.87 | $911,971 | |
| Aug 25, 2025 | ORBIMED ADVISORS LLC Director | Purchase | 5,255,106 | $0.87 | $4,559,855 | |
| Aug 25, 2025 | ORBIMED ADVISORS LLC Director | Purchase | 3,073,298 | — | — | |
| Aug 25, 2025 | ORBIMED ADVISORS LLC Director | Purchase | 15,366,490 | — | — | |
| Aug 25, 2025 | ORBIMED ADVISORS LLC Director | Purchase | 2,022,277 | — | — | |
| Aug 25, 2025 | ORBIMED ADVISORS LLC Director | Purchase | 10,111,384 | — | — | |
| Aug 25, 2025 | Ashiya Mona Director | Purchase | 1,051,021 | $0.87 | $911,971 | |
| Aug 25, 2025 | Ashiya Mona Director | Purchase | 5,255,106 | $0.87 | $4,559,855 | |
| Aug 25, 2025 | Ashiya Mona Director | Purchase | 3,073,298 | — | — | |
| Aug 25, 2025 | Ashiya Mona Director | Purchase | 15,366,490 | — | — | |
| Aug 25, 2025 | Ashiya Mona Director | Purchase | 2,022,277 | — | — | |
| Aug 25, 2025 | Ashiya Mona Director | Purchase | 10,111,384 | — | — |
“Alert” means a voluntary, unscheduled transaction according to the filing; it is not an investment recommendation. Official source: SEC EDGAR.